Intersect ENT (NSDQ:XENT) shares plunged today after the company said it failed to meet the primary endpoint in a study of its Ascend investigational drug-coated sinus balloon.
The 70-person, randomized, double-blind trial was designed to compared treatment with Intersect ENT’s DCB when randomized against an uncoated balloon control. The study missed the primary endpoint, frontal sinus patency grade at 30 days, but did show significant differences in secondary endpoints related to its mometasone furoate coating.
Get the full story at our sister site, Drug Delivery Business News.